SOURCE: UV Flu Technologies, Inc.
CENTERVILLE, MA–(Marketwire – October 19, 2010) – UV Flu Technologies, Inc. (
The XV Beacon Hotel (www.xvbeacon.com) is a 2010 recipient of a Condé Nast award of excellence, and was ranked in 2009 as “#4 Top 20 Business Hotel in the World” by Travel & Leisure Magazine, and “#5 World’s Best Small Hotel: US and Canada” by Travel & Leisure Magazine, alongside numerous awards from industry leading advisors such as Fodor’s, Forbes Traveller, American Express and many others.
Hotel management noted that, “Cold and flu season may be coming on strong, but for allergy sufferers the battle against sniffles and watery eyes never ends. Now XV Beacon in Boston is taking up arms for severely allergic guests with NEW Hypo-Allergenic Guest Rooms courtesy of the ViraTech UV-400 advanced air purification system. This is just the latest example of how the award-winning boutique hotel on Beacon Hill puts the comfort of its guests above everything else.”
The ViraTech UV-400 is a breath of fresh air for severely allergic guests. Approved by Edison Testing Laboratories and certified as a medical device by the FDA, the otherwise inconspicuous air filter kills more than 99% of indoor airborne bacteria while significantly reducing sinus-irritating particles and odors.
The XV Beacon plans to employ the ViraTech UV-400 upon request to “prep” guest rooms for a one-hour period prior to arrival on a complimentary basis and for a small fee will make the unit available for continuous use to ensure their room remains nearly allergen-free throughout their entire stay.
UV Flu Technologies Company President & CEO John J. Lennon stated, “As we head toward the time of year where holiday travel plans coincide with the onset of flu and cold season, the efficacy of our product can offer concerned hotel guests newer, healthier choices never before available when it comes to making their accommodation plans. We are thrilled that such a well-regarded property as the XV Beacon has the vision and leadership to see the potential benefits our product can provide their guests both at this time of year, but especially for allergy sufferers year round. We anticipate this market segment to grow exponentially as other properties grasp the significance of this new technology as we head towards 2011.”
Further details regarding the Company’s business, financial reports and agreements are filed as part of the Company’s continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission’s (“SEC”) EDGAR database.
About UV Flu Technologies, Inc. (
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality (“IAQ”) industry sector. The Company manufactures the ViraTech UV-400, which utilizes high-intensity germicidal ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria at rates exceeding 99.2% on a first-pass basis. The product also is highly effective in reducing odors and VOC’s, or Volatile Organic Compounds, such as acetone, benzene and formaldehyde. ViraTech UV-400 is a Class II medical device and is available without a prescription.
Notice Regarding Forward-Looking Statements
This news release contains “forward-looking statements” as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
ON BEHALF OF THE BOARD
UV Flu Technologies, Inc.
John J. Lennon, President & CEO
Geaux IR Services, Inc.